Confidently meet the specific needs and tight timelines for your RNA or peptide sterile manufacturing with Symbiosis as your trusted partner.
There are many exciting and dynamic biotechnology companies developing the next generation of RNA and peptide therapies. However, these amazing therapies often have challenging manufacturing and handling requirements that require specialist help.
Overcome these challenges with a trusted and established partner by your side. At Symbiosis, we are backed by years of experience and expertise in handling both RNA and peptide-based projects.
Our flexible GMP aseptic manufacturing facility has specialist capabilities and state-of-the-art equipment that helps you get your therapy to patients quickly.
Peptides are short polymer chains of amino acids that serve many therapeutic purposes within the body, such as hormones, growth factors, and anti-infectives.
These therapies can be developed chemically or biologically in a similar way to recombinant proteins. Further modifications using lipids or polyethylene glycol (PEG) chains can enhance bioavailability and/or stability.
RNA therapies utilize short sequences of RNA for therapeutic benefit, most notably used in the mRNA-based vaccine against SARS-CoV-2. This type of treatment can also be used to stimulate an immune response against some cancers and transiently restore cellular functionality.
As the output of the mRNA treatment is the expression of a protein in part or as a whole, these are considered coding RNA sequences, but non-coding RNA sequences can also be used.
Antisense RNA molecules bind to complementary RNA sequences within the cell, for example, to cause the reduction in transcription of a particular protein target. Interfering RNA (RNAi) sequences can also be utilized to regulate gene expression.
RNA therapies are most often delivered to the cell in lipid nanoparticles, but viral delivery mechanisms may also be used.
